CN111050757A - 用于共递送抗炎分子与核酸以改善基因递送结果的矿物质涂覆微粒 - Google Patents

用于共递送抗炎分子与核酸以改善基因递送结果的矿物质涂覆微粒 Download PDF

Info

Publication number
CN111050757A
CN111050757A CN201880056388.3A CN201880056388A CN111050757A CN 111050757 A CN111050757 A CN 111050757A CN 201880056388 A CN201880056388 A CN 201880056388A CN 111050757 A CN111050757 A CN 111050757A
Authority
CN
China
Prior art keywords
mineral
interferon
combinations
composition
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880056388.3A
Other languages
English (en)
Chinese (zh)
Inventor
W·L·墨菲
A·S·卡里尔
X·于
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CN111050757A publication Critical patent/CN111050757A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880056388.3A 2017-07-05 2018-07-05 用于共递送抗炎分子与核酸以改善基因递送结果的矿物质涂覆微粒 Pending CN111050757A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528566P 2017-07-05 2017-07-05
US62/528,566 2017-07-05
PCT/US2018/040928 WO2019010310A1 (en) 2017-07-05 2018-07-05 MINERAL-COATED MICROPARTICLES FOR CO-ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES AND NUCLEIC ACIDS TO IMPROVE GENE DELIVERY RESULTS

Publications (1)

Publication Number Publication Date
CN111050757A true CN111050757A (zh) 2020-04-21

Family

ID=64950341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880056388.3A Pending CN111050757A (zh) 2017-07-05 2018-07-05 用于共递送抗炎分子与核酸以改善基因递送结果的矿物质涂覆微粒

Country Status (6)

Country Link
US (2) US11065208B2 (https=)
EP (1) EP3648750A4 (https=)
JP (1) JP2020526515A (https=)
CN (1) CN111050757A (https=)
CA (1) CA3068917A1 (https=)
WO (1) WO2019010310A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115227676A (zh) * 2022-07-04 2022-10-25 浙江大学 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187344A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
WO2022031594A1 (en) * 2020-08-06 2022-02-10 Dianomi Therapeutics, Inc. Compositions and methods for vaccine delivery
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003475A1 (en) * 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition of innate immune response
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317807A1 (en) * 2007-06-22 2008-12-25 The University Of Hong Kong Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN104508131B (zh) 2012-05-21 2018-11-23 加利福尼亚大学董事会 通过合成的自我复制的RNA形成人iPS细胞
EP3046933B1 (en) * 2013-09-18 2019-02-27 BCN Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003475A1 (en) * 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition of innate immune response
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115227676A (zh) * 2022-07-04 2022-10-25 浙江大学 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用
CN115227676B (zh) * 2022-07-04 2023-10-24 浙江大学 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用

Also Published As

Publication number Publication date
US20200170958A1 (en) 2020-06-04
EP3648750A4 (en) 2021-05-26
US11065208B2 (en) 2021-07-20
EP3648750A1 (en) 2020-05-13
JP2020526515A (ja) 2020-08-31
US11779542B2 (en) 2023-10-10
US20210353549A1 (en) 2021-11-18
CA3068917A1 (en) 2019-01-10
WO2019010310A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
Li et al. Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs
DE60130743T2 (de) Mikrokugeln zur aktiven embolisierung
KR102229618B1 (ko) 지질 조성물
Kong et al. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis
US20250213496A1 (en) Lipid nanoparticles and preparation methods and use thereof
TW201731491A (zh) 用於藥物傳遞之脂質奈米粒子的製造方法
JP2008520600A (ja) 局所投与のための医薬組成物におけるまたはそれに関する改善
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
US20220259597A1 (en) Oligonucleotide antagonists for rna guided genome editing
US20120040004A1 (en) Treatment of radiation-induced fibrosis
Lei et al. Exosome-like vesicles encapsulated with specific microRNAs accelerate burn wound healing and ameliorate scarring
US20190358344A1 (en) Mineral coated microparticles for sustained delivery of steroids
KR20190130643A (ko) 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자
JP2010511692A (ja) イオントフォレシスを通じての核酸の強化された網膜送達
US11628227B2 (en) Mineral coated microparticles for gene delivery in chronic wound therapy
JP2011505917A (ja) イオントフォレシスによってｓｉＲＮＡを送達する方法
CN120754284A (zh) 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒
HK40020489A (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
Zhang et al. Topical application of insulin encapsulated by chitosan-modified PLGA nanoparticles to alleviate alkali burn-induced corneal neovascularization
US20230092306A1 (en) Substance delivery carrier and composition
KR20200093611A (ko) 안구 섬유증의 치료를 위한 miR29 모방체
CN104288095B (zh) 一种用于膀胱内递送药理活性物质的漂浮凝胶及其药物制剂
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
Hattori et al. Effect of chondroitin sulfate on siRNA biodistribution and gene silencing effect in mice after injection of siRNA lipoplexes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020489

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200421

RJ01 Rejection of invention patent application after publication